Briefing
Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients
In a larger surgical HNSCC series from the LIONESS group, plasma ctDNA collected at least 14 days after surgery identified 91.3% of recurrences, with lead times up to 500 days.
- Design: Evidence level 2
- Assay: Not named in the abstract
NPJ Precis OncolPubMed 41634365DOI 10.1038/s41698-026-01309-0